TY  - JOUR
A1  - Hohmann, Cynthia
A1  - Pinart, Mariona
A1  - Tischer, Christina
A1  - Gehring, Ulrike
A1  - Heinrich, Joachim
A1  - Kull, Inger
A1  - Melén, Eric
A1  - Smit, Henriette A.
A1  - Torrent, Maties
A1  - Wijga, Alet H.
A1  - Wickman, Magnus
A1  - Bachert, Claus
A1  - Lødrup Carlsen, Karin C.
A1  - Carlsen, Kai-Håkon
A1  - Bindslev-Jensen, Carsten
A1  - Eller, Esben
A1  - Esplugues, Ana
A1  - Fantini, Maria Pia
A1  - Annesi-Maesano, Isabella
A1  - Momas, Isabelle
A1  - Porta, Daniela
A1  - Vassilaki, Maria
A1  - Waiblinger, Dagmar
A1  - Sunyer, Jordi
A1  - Antó, Josep M.
A1  - Bousquet, Jean
A1  - Keil, Thomas
T1  - The Development of the MeDALL Core Questionnaires for a Harmonized Follow-Up Assessment of Eleven European Birth Cohorts on Asthma and Allergies
JF  - International Archives of Allergy and Immunology
N2  - Background: Numerous birth cohorts have been initiated in the world over the past 30 years using heterogeneous methods to assess the incidence, course and risk factors of asthma and allergies. The aim of the present work is to provide the stepwise proceedings of the development and current version of the harmonized MeDALL-Core Questionnaire (MeDALL-CQ) used prospectively in 11 European birth cohorts. Methods: The harmonization of questions was accomplished in 4 steps: (i) collection of variables from 14 birth cohorts, (ii) consensus on questionnaire items, (iii) translation and back-translation of the harmonized English MeDALL-CQ into 8 other languages and (iv) implementation of the harmonized follow-up. Results: Three harmonized MeDALL-CQs (2 for parents of children aged 4-9 and 14-18, 1 for adolescents aged 14-18) were developed and used for a harmonized follow-up assessment of 11 European birth cohorts on asthma and allergies with over 13,000 children. Conclusions: The harmonized MeDALL follow-up produced more comparable data across different cohorts and countries in Europe and will offer the possibility to verify results of former cohort analyses. Thus, MeDALL can become the starting point to stringently plan, conduct and support future common asthma and allergy research initiatives in Europe.
KW  - harmonization
KW  - MeDALL
KW  - european birth cohorts
KW  - asthma
KW  - allergy
KW  - questionnaire assessment
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196594
SN  - 1018-2438
SN  - 1423-0097
VL  - 163
IS  - 3
ER  - 
TY  - JOUR
A1  - Zhang, Nan
A1  - Van Crombruggen, Koen
A1  - Holtappels, Gabriele
A1  - Lan, Feng
A1  - Katotomichelakis, Michail
A1  - Zhang, Luo
A1  - Högger, Petra
A1  - Bachert, Claus
T1  - Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo
JF  - PLOS ONE
N2  - Background: Topical glucocorticosteroids are the first line therapy for airway inflammation. Modern compounds with higher efficacy have been developed, but head-to-head comparison studies are sparse. 
Objective: To compare the activity of two intranasal glucocorticoids, fluticasone furoate (FF) and mometasone furoate (MF) with respect to the inhibition of T helper (Th)1, Th2 and Th17 cytokine release in airway mucosa. 
Methods: We used an ex-vivo human nasal mucosal tissue model and employed pre-and post-Staphylococcus aureus enterotoxin B (SEB)-challenge incubations with various time intervals and drug concentrations to mimic typical clinical situations of preventive or therapeutic use. 
Results: At a fixed concentration of 10(-10) M, FF had significantly higher suppressive effects on interferon (IFN)-gamma,interleukin (IL)-2 and IL-17 release, but not IL-5 or tumor necrosis factor (TNF)-alpha, vs. MF. While the maximal suppressive activity was maintained when FF was added before or after tissue stimulation, the cytokine suppression capacity of MF appeared to be compromised when SEB-induced cell activation preceded the addition of the drug. In a pre-challenge incubation setting with removal of excess drug concentrations, MF approached inhibition of IL-5 and TNF-alpha after 6 and 24 hours while FF maximally blocked the release of these cytokines right after pre-incubation. Furthermore, FF suppressed a wider range of T helper cytokines compared to MF. 
Conclusion: The study demonstrates the potential of our human mucosal model and shows marked differences in the ability to suppress the release of various cytokines in pre-and post-challenge settings between FF and MF mimicking typical clinical situations of preventive or therapeutic use.
KW  - allergic rhinitis
KW  - human receptor kinetics
KW  - staphylococcus aureus
KW  - intranasal corticosteroids
KW  - cells
KW  - propionate
KW  - secretion
KW  - affinity
KW  - therapy
KW  - spray
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116779
VL  - 9
IS  - 4
ER  -